ustekinumab
- 최초 등록일
- 2012.09.12
- 최종 저작일
- 2012.03
- 29페이지/ MS 파워포인트
- 가격 1,000원
소개글
스테렐라의 건선치료 작용기전 및 안전성
목차
없음
본문내용
Ustekinumab
Human monoclonal antibody
It is directed against IL-12 and IL-23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
Ix: severe plaque psoriasis
Phase II studies for multiple sclerosis , sarcoidosis and psoriatic arthritis.
Ustekinumab
Development of T helper (Th)1, Th2, Th17 and iTreg cells from naive CD4+ T cells.
Brand S Gut 2009;58:1152-1167
Copyright ⓒ BMJ Publishing Group Ltd & British Society of Gastroenterology. All rights reserved.
Background and Objective
Ustekinumab targets interleukin(IL)-12 and IL-23 in the treatment of moderate to severe psoriasis.
To evaluate overall pooled study data to assess the safty profile of ustekinumab through 3 years of treatment.
We sought to evaluate the impact of ustekinumab on infections and malignancies, both theoretical risks of blocking IL-12 and IL-23, in patients exposed up to 3 years.
Methods
Cumulative safty data were pooled from studies 3117 ustekinumab-treated patients.
Rates of infections and malignancies were evaluated in cumulative safety data from 3117 ustekinumab-treated patients across 4 studies.
참고 자료
없음